摘要
[目的]研究使用低分子量肝素进行血液透析抗凝的临床疗效。[方法]90例维持性血液透析患者通过自身对照,观察应用低分子量肝素前后透析器凝血程度、容积下降率,血红蛋白、血小板、全血部分凝血酶时间(APTT)、凝血酶时间(TT)、凝血酶原时间(PT)、谷丙转氨酶(ALT)。[结果]使用抗凝进行血液透析,每例患者的透析器均顺利使用4次未发生透析器及管路凝血,用药前后TT、APTT、ALT、血红蛋白、血小板计数无明显变化(P﹥0.05);透析器容积下降率﹤15.45%,未发现出血病例。[结论]血液透析开始时,一次性给予低分子量肝素抗凝,使用方便、安全有效。
[Objective] To study on the clinical therapeutic effect of low molecular weight heparin on anticoagulation during hematodialysis. [ Methods] 90 patients undergoing maintenance hemodialysis were enrolled to observe the therapeutic effect by own control method. The blood clotting grade and reducing rate of the volume in the dialyser, the levels of hemoglobin, platelet count, activated partial thromboplastin time （APTF）, thrombin time （TT）, prothrombin time （PT）, alanine aminotransferase （ALT） were observed before and after conducting with low molecular weight heparin administration. [ Results] By using anticoagulant during hematodialysis, the dialyser of each patient could be used four times without coagulation in the dialysers or channels. The TT, APTF, ALT, hemoglobin, and platelets count did not found significant difference before and after treatment; The decreased rate of the was below 15.45%, but no case with bleeding during the treatment was found. [Conclusion] Patients treated with low molecular weight heparin administrated showed to be safe, convenient and effective once for all at the beginning of hemodialysis.
出处
《现代预防医学》
CAS
北大核心
2008年第10期1976-1977,共2页
Modern Preventive Medicine
关键词
低分子量肝素
血液透析
抗凝剂
Low molecular weight heparin
Hemodialysis
Anticoagulant
